Find Hematology Drugs in Phase III Clinical Development

Lead Product(s): Danicopan

Therapeutic Area: Hematology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Alexion Pharmaceuticals

Deal Size: $930.0 million Upfront Cash: $930.0 million

Deal Type: Acquisition January 28, 2020

Details:

Acquisition adds two clinical-stage Factor D inhibitors to Alexion’s pipeline and provides promising development platform for additional complement-mediated diseases.

Lead Product(s): Desidustat

Therapeutic Area: Hematology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: China Medical System Holdings Limited

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement January 20, 2020

Details:

Under the terms and conditions of the agreement, CMS will be responsible for development, registration and commercialisation of Desidustat in Greater China.

Lead Product(s): Avatrombopag

Therapeutic Area: Hematology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 13, 2020

Details:

Enrollment remains ongoing for the phase 3 clinical study of avatrombopag for the treatment of patients with CIT.

Lead Product(s): Nomacopan

Therapeutic Area: Hematology

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 10, 2020

Details:

All patients treated with nomacopan achieved the primary endpoint of transfusion independence.

Lead Product(s): Eculizumab

Therapeutic Area: Hematology

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 09, 2020

Details:

To date, SB12 (AMT904) is the only biosimilar candidate referencing Soliris® (eculizumab) to be granted IND approval in China.

Lead Product(s): Ferric Maltol

Therapeutic Area: Hematology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Beijing Aosaikang Pharmaceutical

Deal Size: $62.8 million Upfront Cash: $11.4 million

Deal Type: Licensing Agreement January 08, 2020

Details:

Shield Therapeutics enters into an exclusive licence agreement for its lead product Feraccru®/Accrufer® with Beijing Aosaikang Pharmaceutical Co. Ltd. .

Lead Product(s): APL 2

Therapeutic Area: Hematology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 07, 2020

Details:

In a head-to-head phase 3 trial after 16 weeks, hemoglobin levels in the pegcetacoplan arm had increased by 3.8 g/dL over the Soliris group, resulting in the trial hitting its primary endpoint.